Drug Trial Radar · NCT02608268
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
252
Actual
Start
Nov 23, 2015
Primary completion
Aug 30, 2022
Study completion Aug 30, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors
Conditions
- Advanced Malignancies
Interventions
MBG453Drug
Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
PDR001Drug
Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
DecitabineDrug
commercially available chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I-Ib and Dose Ranging Part: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment PeriodTime frame: From first dose of study medication up to 30 days after last dose, with a maximum duration of 2 years for sabatolimab and 5 years for sabatolimab in combination with spartalizumab
- Phase I-Ib: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 28 days (sabatolimab single agent) and 56 days (sabatolimab+spartalizumab)
- Phase I-Ib and Dose Ranging Part: Number of Participants With Dose Reductions and Dose Interruptions of SabatolimabTime frame: From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab
- Phase Ib: Number of Participants With Dose Reductions and Dose Interruptions of SpartalizumabTime frame: From first dose of study medication up to last dose, with a maximum duration of 4.9 years
- Phase I-Ib and Dose Ranging Part: Dose Intensity of SabatolimabTime frame: From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab
- Phase Ib: Dose Intensity of SpartalizumabTime frame: From first dose of study medication up to last dose, with a maximum duration of 4.9 years
- Phase II: Overall Response Rate (ORR) Per RECIST v1.1Time frame: From start of treatment until end of treatment, assessed up to 2.9 years
Locations
14 sites in 9 countries. Site status is shown where the registry gives one.
Sidney Kimmel CCC At JH Sidney Kimmel CCC
Baltimore, Maryland
Dana Farber Cancer Institute DFCI - Brookline
Boston, Massachusetts
UT M.D Anderson Cancer Center
Houston, Texas
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Leiden, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Geneva, Switzerland
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.